Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New Multi-Biomarker Class Approach Improves Cancer Detection

By LabMedica International staff writers
Posted on 25 Nov 2024

Cancer is expected to become the leading cause of death in the U. More...

S. by 2030. Only about 14% of all cancers in the U.S. are detected through screening, highlighting a significant gap in patient care. Multi-cancer early detection (MCED) testing presents the most promising opportunity to address this issue. Now, recent findings from three studies highlight significant progress in developing an MCED test.

Exact Sciences (Madison, WI, USA), a leading cancer screening and diagnostic solutions provider, presented three abstracts at the AACR Special Conference in Cancer Research: Liquid Biopsy. These studies provide encouraging data on the potential of an MCED test. One of the studies evaluated a new multi-biomarker class approach and demonstrated improved sensitivity for detecting early-stage and overall cancers. The study showed that incorporating a DNA mutation reflex approach with methylation and protein (MP) test results in the MCED test increased early-stage cancer sensitivity. Specifically, the test improved sensitivity by 28% for stage I cancers and 12.5% for early-stage cancers (stages I and II) at a 98.5% specificity rate in a case-control study. This highlights the potential of a three-biomarker class (DNA methylation, protein, DNA mutation reflex, or MP-r) test for better-detecting cancers at earlier stages.

This research contributes to the ongoing development of Exact Sciences' Cancerguard test, which aims to utilize the combined sensitivity of multiple biomarker classes to detect more cancers in their early stages. The Cancerguard test is designed to detect multiple cancers from a single blood draw in their earliest stages. Building on decades of research, Exact Sciences seeks to improve early detection by using a multi-biomarker approach. The test will feature a streamlined and standardized imaging-based diagnostic pathway, potentially reducing the need for follow-up procedures. It will also focus on high specificity to minimize false positives while detecting a range of cancers, particularly those with the greatest impact on health.

Moreover, new modeling data suggests that adding MCED testing to recommended screenings could significantly reduce the incidence of stage IV cancers and, consequently, cancer mortality over the next decade. The modeling predicts a 42% reduction in stage IV cancer incidence and a 17% decrease in 10-year cancer mortality with the integration of MCED testing into standard care. Another analysis from the DETECT-A (Detecting Cancers Early Through Elective Mutation-based Blood Collection and Testing) study indicates that incorporating MCED testing enhances guideline-recommended lung cancer screenings without reducing adherence to current practices. The DETECT-A study, which enrolled over 10,000 women with no prior cancer history, was the first large, prospective, interventional study to use a blood test for detecting multiple cancer types in a real-world setting. The CancerSEEK test, the MCED test used in DETECT-A, is a precursor to Exact Sciences’ Cancerguard test, now under development.

“The Exact Sciences team is committed to taking a rigorous, comprehensive approach to multi-cancer screening. The new data answer key questions about the impact we can anticipate with MCED testing if integrated into clinical practice,” said Tom Beer, M.D., chief medical officer and vice president, multi-cancer early detection, Exact Sciences.

Related Links:
Exact Sciences


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.